Neoplasm.News

Anti-CD33 ADC × Myeloid × Clear all

2 Announcements

FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients

Drug: MYLOTARG (gemtuzumab ozogamicin) · Anti-CD33 antibody-drug conjugate
Condition: Myeloid

FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML

Drugs: Mylotarg (gemtuzumab ozogamicin) · Anti-CD33 antibody-drug conjugate, daunorubicin · Anthracycline, cytarabine · Pyrimidine analog
Condition: Myeloid